HLA-E and Miyoshi myopathy: Notably, the increased expression of HLA-E by CX-5461 was attenuated by co-treatment with Lenalidomide, an immunomodulatory drug, and by Panobinostat, a histone deacetylase inhibitor, both capable of further enhancing NK cell activity against MM cells.